Joseph P Dougherty

US Patent:

6613569, Sep 2, 2003

Filed:

Mar 5, 2002

Appl. No.:

09/979681

Inventors:

Joseph P Dougherty - Hampton NJ
Martin E Adelson - Hillsborough NJ
Malvika Kaul - Piscataway NJ
AnnMarie L Pacchia - Piscataway NJ
Yacov Ron - East Brunswick NJ

Assignee:

University of Medicine and Dentistry of New Jersey - New Brunswick NJ

International Classification:

C12N 508

US Classification:

435457, 435 691, 435 693, 4352351, 435236, 4353201, 435366, 435369, 435325, 435440, 435458, 435456, 435377, 435367, 514 44, 536 2372

Abstract:

Novel packaging cell lines for production of lentiviral vectors are disclosed. The cell lines utilize an ecdysone-inducible system for virus production, thereby avoiding the cytotoxic effect of unregulated expression of certain envelope proteins and lentiviral proteins. Various embodiments of the cell lines are disclosed, which are suitable for different purposes that range from in vitro screening assays to gene therapy in vivo.

US Patent:

7198909, Apr 3, 2007

Filed:

Oct 29, 1999

Appl. No.:

09/830176

Inventors:

Yacov Ron - East Brunswick NJ, US
Joseph P. Dougherty - Hampton NJ, US

Assignee:

University of Medicine & Dentistry of New Jersey - New Brunswick NJ

International Classification:

C12P 21/06
C12P 21/00

US Classification:

435 691, 435 701

Abstract:

A long-lived, myeloid-committed stem cell population is disclosed. Also disclosed are methods and compositions for targeting this population with retrovirus vectors in gene therapy protocols for correcting congenital disorders of myeloid system and for potentiating immune responses to defined tumor and viral antigens.

US Patent:

8247167, Aug 21, 2012

Filed:

Nov 27, 2006

Appl. No.:

12/096245

Inventors:

Joseph P. Dougherty - Milford NJ, US
Sofiya Micheva-Viteva - Los Alamos NM, US
Stuart W. Peltz - Califon NJ, US
Yacov Ron - East Brunswick NJ, US
Annmarie L. Pacchia - Buffalo NY, US

Assignee:

University of Medicine and Dentistry of New Jersey - New Brunswick MA

International Classification:

C12N 7/01
C12N 15/867

US Classification:

435 5, 4352351

Abstract:

Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.

US Patent:

20130040385, Feb 14, 2013

Filed:

Jul 17, 2012

Appl. No.:

13/551257

Inventors:

Joseph P. Dougherty - Milford NJ, US
Sofiya Micheva-Viteva - Los Alamos NM, US
Stuart W. Peltz - Califon NJ, US
Yacov Ron - Califon NJ, US
Annmarie L. Pacchia - Buffalo NY, US

Assignee:

UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - New Brunswick NJ

International Classification:

C12N 5/10

US Classification:

435325

Abstract:

Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.

US Patent:

56679980, Sep 16, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/477363

Inventors:

Joseph Dougherty - Hampton NJ
Ming-Ling Kuo - Taipei, TW
Natalie Sutkowski - Gloucester MA
Yacov Ron - East Brunswick NJ

Assignee:

University of Medicine and Dentistry of New Jersey - Newark NJ

International Classification:

C12N 510
C12N 1564

US Classification:

4351723

Abstract:

The present invention pertains to a method for efficiently introducing exogenous genes into primary lymphoid cells without drug selection which comprises the steps (a) deriving a retroviral vector and a helper cell combination that will yield a level of virus production in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml by transfecting a vector into a helper cell followed by selection, isolation of cell clones, and determination of viral titers to identify which virus-producing cell lines produce a virus titer in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml; (b) isolating a lymphoid cell subpopulation which can repopulate a specific lymphoid lineage or is a long-lived population by treating a suspension of lymphoid cells with a monoclonal antibody which removes undesired lymphoid cells to obtain an enriched lymphoid subpopulation; (c) culturing the enriched lymphoid subpopulation from step (b) with growth factors specific to the lymphoid subpopulation; (d) co-cultivating the lymphoid subpopulation from step (c) with a lawn of irradiated virus-producing cell line from step (a) to produce an infected lymphoid subpopulation; and (e) harvesting the infected lymphoid subpopulation. The invention further relates to a population of transfected lymphocytes, in which greater than about 90% of the lymphocytes contain a provirus.

US Patent:

56889151, Nov 18, 1997

Filed:

Jun 1, 1995

Appl. No.:

8/457482

Inventors:

Yakov Ron - East Brunswick NJ
Joseph Dougherty - Hampton NJ

Assignee:

The University of Medicine and Dentistry of New Jersey - Newark NJ

International Classification:

C12N 500
C12N 508
C12Q 104

US Classification:

530380

Abstract:

Long term culture of resting T lymphocytes. The present invention provides methods and compositions for maintaining resting, mature T lymphocytes (cells) for long term in the absence of mitogens, antigens, or stimulatory cytokines, in which the T cells maintaining their ability to respond to nitrogens and allogenic cells. T cells cultured under such conditions can be used as target cells for retroviral vector-mediated gene transfer and implemented in certain gene therapy applications. The culturing conditions described herein allow for the continuous availability of T lymphocytes for various pharmacological, diagnostic, gene therapy, and experimental purposes, and can be utilized for any application requiring non-stimulated T lymphocytes. In specific examples, umbilical cord blood and peripheral blood T lymphocytes and endothelial-like adherent monocytes are cultured in DMEM, 2% 2-mercaptoethanol containing either 20% horse serum, or RPMI 2% 2-ME containing 10% fetal calf serum supplemented with basic fibroblast growth factor for up to three months.

US Patent:

56862806, Nov 11, 1997

Filed:

Sep 8, 1994

Appl. No.:

8/302232

Inventors:

Joseph Dougherty - Hampton NJ
Ming-ling Kuo - Piscataway NJ
Natalie Sutkowski - Edison NJ
Yacov Ron - East Brunswick NJ

Assignee:

University of Medicine & Dentistry of New Jersey - Newark NJ

International Classification:

C12N 510
C12N 1564

US Classification:

4351723

Abstract:

The present invention pertains to a method for efficiently introducing exogenous genes into primary lymphoid cells without drug selection which comprises the steps (a) deriving a retroviral vector and a helper cell combination that will yield a level of virus production in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml by transfecting a vector into a helper cell followed by selection, isolation of cell clones, and determination of viral titers to identify which virus-producing cell lines produce a virus titer in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml; (b) isolating a lymphoid cell subpopulation which can repopulate a specific lymphoid lineage or is a long-lived population by treating a suspension of lymphoid cells with a monoclonal antibody which removes undesired lymphoid cells to obtain an enriched lymphoid subpopulation; (c) culturing the enriched lymphoid subpopulation from step (b) with growth factors specific to the lymphoid subpopulation; (d) co-cultivating the lymphoid subpopulation from step (c) with a lawn of irradiated virus-producing cell line from step (a) to produce an infected lymphoid subpopulation; and (e) harvesting the infected lymphoid subpopulation.

US Patent:

59069287, May 25, 1999

Filed:

Mar 19, 1996

Appl. No.:

8/586754

Inventors:

Joseph Dougherty - Hampton NJ
Yacov Ron - East Brunswick NJ

Assignee:

University of Medicine and Dentistry of New Jersey - Newark NJ

International Classification:

C12N 1510
C12N 1563
C12N 1586
C12N 510

US Classification:

4351723

Abstract:

The present invention pertains to a method for efficiently introducing exogenous genes into primary lymphoid cells without drug selection which comprises the steps (a) deriving a retroviral vector and a helper cell combination that will yield a level of virus production in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml by transfecting a vector into a helper cell followed by selection, isolation of cell clones, and determination of viral titers to identify which virus-producing cell lines produce a virus titer in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml; (b) isolating a lymphoid cell subpopulation which can repopulate a specific lymphoid lineage or is a long-lived population by treating a suspension of lymphoid cells with a monoclonal antibody which removes undesired lymphoid cells to obtain an enriched lymphoid subpopulation; (c) culturing the enriched lymphoid subpopulation from step (b) with growth factors specific to the lymphoid subpopulation; (d) co-cultivating the lymphoid subpopulation from step (c) with a lawn of irradiated virus-producing cell line from step (a) to produce an infected lymphoid subpopulation; and (e) harvesting the infected lymphoid subpopulation. The invention further relates to a population of transfected lymphocytes, in which greater than about 90% of the lymphocytes contain a provirus.